Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05433142 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv11
  2. Trial sites expanded: 23 → 26 locationsv10
  3. Enrollment target: 95 to 307 Primary completion date: Feb 2026 to Feb 2027 · Study sites: 8 to 23 · Completion date: Nov 2027 to Dec 2028 · 2 morev9 Show 5 more changesShow less
    • Primary completion date: Feb 2026 to Feb 2027
    • Study sites: 8 to 23
    • Completion date: Nov 2027 to Dec 2028
    • Study description revised
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Apr 2025 to Feb 2026 Completion date: Mar 2027 to Nov 2027v8 Show 1 more changeShow less
    • Completion date: Mar 2027 to Nov 2027
  5. Study sites revised (8)v7 See this version in full on ClinicalTrials.gov ↗
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 7 to 8 Completion date: Apr 2026 to Mar 2027 · Eligibility criteria shortened, about 51 words · Secondary endpoints: details revised at 3 of 5 entries · 1 morev6 Show 4 more changesShow less
    • Completion date: Apr 2026 to Mar 2027
    • Eligibility criteria shortened, about 51 words
    • Secondary endpoints: details revised at 3 of 5 entries
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 3 to 7v5
  3. Site contacts updated at 1 of 3 sitesv4
  4. Re-verified, no change to tracked fieldsv3
  5. Primary endpoints revised (2) Study sites: 2 to 3 · Start date changed from estimate of Jun 2022 to Jun 13, 2022 · Secondary endpoints revised (5)v2 Show 3 more changesShow less
    • Study sites: 2 to 3
    • Start date changed from estimate of Jun 2022 to Jun 13, 2022
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xencor
10 trials monitored
See all monitored trials
Kidney Cancer
772 trials monitored
See 53 trials at risk
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Trial Details
NCT Number NCT05433142
Lead Sponsor Xencor, Inc.
Conditions Clear Cell Renal Cell Carcinoma
Enrollment 307 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov